Diab A, Ascierto PA, Maio M, Abdel-Wahab R, et al. Randomized, Open-Label, Phase III Study of Tilsotolimod in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced Refractory Melanoma (ILLUMINATE-301). J Clin Oncol 2025 Mar 6:JCO2400727. doi: 10.1200/JCO.24.00727.
PMID: 40048691